Eli Lilly & Co(IT:1LLY)
€1,231.40-36.60 (-2.89%)
IT:1LLY
Eli Lilly & Co stock drug pipeline
€1,231.40
At close:-36.60 (-2.89%)
Eli Lilly & Co (1LLY) Drug Pipeline
10 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Eli Lilly And Company (IT:1LLY) have in its pipeline
Eli Lilly & Co IT:1LLY is currently developing the following drugs: Ly3839056 Iv, Ly3839056 Sc, Brenipatide, Ly3537031, Imlunestrant, Omeprazole, Ly3484356, Ly4247147, Ly3819469, Lepodisiran, Ly3841136, Eloralintide, Ly3873862, Cyp450 Drug Cocktail, Ly4167586, Tirzepatide, Eloralintide And Tirzepatide, Tirzepatide, Ly3841136, Eloralintide, Eloralintide And Tirzepatide, Midazolam, Ly5625573, [¹⁴C]-Ly4515100 Oral Solution, Ly4515100 Tablet, [¹⁴C]-Ly4515100 Iv, Florbetapir F18, Florbetaben F 18, Ly4560736, Donanemab, Ly3002813, Vepugratinib, Ly3866288, Selpercatinib, Tirzepatide, Oxaliplatin, Cetuximab, 5-Fluorouracil, Olomorasib, Leucovorin/Levofolinate Calcium, Ly3537982, Ly4329090, Combined Oral Contraceptive, Eloralintide, Ly3841136, Tirzepatide, Acetaminophen, Ly5625575, Abemaciclib Tablet, Abemaciclib Oral Granules, Orforglipron, Ly3502970, Olomorasib Test, Olomorasib Reference, Ly3537982, Florbetapir F18, Ly4405094, Florbetaben F 18, Clazakizumab, Eloralintide, Macupatide, Ly3532226, Midazolam, Ly4355756, Standard Of Care, Ly3537031, Brenipatide, Acetaminophen, Eloralintide, Ly3841136, Ly4268989, Eloralintide, Ly3841136, Ly4178256, Dulaglutide, Orforglipron, Ly3502970, High-Fat Meal, Tersolisib, Low-Fat Meal, Ly4064809. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

